Deerfield Capital Management
53
58M
46
1.83
11
0.13
28
- Stages of investment
- Areas of investment
Summary
The main office of represented VC is situated in the Rosamond. The fund was located in North America if to be more exact in United States.
The overall number of key employees were 22.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Deerfield Capital Management, startups are often financed by OrbiMed, Polaris Partners, Deerfield. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Perceptive Advisors, Redmile Group. In the next rounds fund is usually obtained by Deerfield, Sutter Hill Ventures, OrbiMed.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Health Diagnostics. The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most popular portfolio startups of the fund, we may highlight Foundation Medicine, Allogene Therapeutics, Alector.
The higher amount of exits for fund were in 2019. The fund is constantly included in 2-6 deals per year. Deals in the range of 50 - 100 millions dollars are the general things for fund. The top activity for fund was in 2018. Considering the real fund results, this VC is 11 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this Deerfield Capital Management works on 19 percentage points more the average amount of lead investments.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 53
- Lead investments
- 11
- Exits
- 28
- Rounds per year
- 1.83
- Follow on index
- 0.13
- Investments by industry
- Health Care (42)
- Biotechnology (38)
- Pharmaceutical (20)
- Medical (19)
- Therapeutics (13) Show 18 more
- Investments by region
-
- United States (46)
- United Kingdom (2)
- Israel (3)
- Canada (1)
- Peak activity year
- 2018
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 17
- Avg. valuation at time of investment
- 39M
- Group Appearance index
- 0.81
- Avg. company exit year
- 11
- Avg. multiplicator
- 1.18
- Strategy success index
- 0.80
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Adaptive Phage Therapeutics | 13 Jun 2023 | Biotechnology, Health Care, Pharmaceutical, Therapeutics | Early Stage Venture | 12M | United States, Maryland, Bethesda |
| Quartet Health | 03 Jan 2018 | Information Technology, Health Care, Hospital, Personal Health, Predictive Analytics | Late Stage Venture | 40M | United States, New York, New York |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.